Imagin Medical Announces Product and Financial Information VANCOUVER, BC, and BOSTON, MA, January 26, 2024 – Imagin Medical Inc., (“Imagin” or “the Company”), a urologic oncology company, announces additional information...
Read More
Rapha Capital BioVentures Fund I, LP (Rapha Capital), and Bigger Capital lead the financing. VANCOUVER, BC, and BOSTON, MA, August 22, 2022 – Imagin Medical Inc., (“Imagin” or the “Company”),...
Read More
Vancouver, B.C. and Boston, MA, November 8, 2021 – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) “Imagin” or the “Company”), a surgical imaging company visualizing cancer in vital new ways...
Read More
Rapha Capital BioVentures Fund I, LP (RCBVFI), Leads New Convertible Note Financing Kevin Slawin, MD, a Leading UroOncologist and Manager of RCBVFI Joins the Board Imagin Medical’s i/Blue™ Imaging System is...
Read More
Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced that the final…
Vancouver, B.C. and Boston, MA, August 17, 2021 – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported that the final...
Read More
Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed the i/Blue Imaging System(TM), an innovative technology designed to significantly improve the way surgeons visualize cancerous cells for more accurate bladder resection….
Vancouver, B.C. and Boston, MA, May 19, 2021 – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported continued progress towards...
Read More
Vancouver, B.C. and Boston, MA, March 16, 2021 – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported continued progress towards...
Read More
Vancouver, B.C. and Boston, MA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD3) (“Imagin” or the “Company”)...
Read More
VANCOUVER, British Columbia, and BOSTON, Jan. 13, 2021 -- via InvestorWire – Imagin Medical (CSE: IME) (OTC: IMEXF) (FRA: DPD2) (the “Company”) announces that critical milestones met in the second...
Read More
VANCOUVER, British Columbia, and BOSTON, Jan. 20, 2021 – via InvestorWire – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (FSE: DPD2) ("Imagin" or the "Company") is pleased to announce that...
Read More
Vancouver, B.C. and Boston, MA, November 10, 2020 – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announced that, further to...
Read More
Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer
Clement Orczyk, DeanBarratt, ChrisBrew-Graves, YiPengHu, AlexFreeman, Neil McCartan, Ingrid Potyka, Navin Ramachandran, Rachael Rodell, Norman R. Williams, Mark Emberton ǁ, and Hashim U. Ahmed
/wp-content/uploads/sites/2/2022/08/Orczyk-et-al-ProRAFT-Trial-J-Urol-Vol.-205-1090-1099-April-2021.pdf
Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
Lotan Y, Chaplin I, Ahmadi H, Meng X, Roberts S, Ladi-Seyedian S, Bagrodia A, Margulis V, Woldu S, Daneshmand S.
BJU Int. 2021 Jan;127(1):108-113. doi: 10.1111/bju.15166. Epub 2020 Aug 6.
https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fpubmed.ncbi.nlm.nih.gov%2f32648957%2f&c=E,1,p6aIPOJ9u0U9VIqE_AgiQqbDZFZ16wx5VmbjSt0KVPKiSOaFO89n6iLubYKOUZUOksfJJQaqDvKXlRLnY5iNv8f8Bjo30vf4cjuOPNdtK7jj&typo=1
Effect of blue-light cystoscopy on contemporary performance of urine cytology.
Freifeld Y, Lotan Y.
BJU Int. 2019 Aug;124(2):251-257. doi: 10.1111/bju.14574. Epub 2018 Oct 21.
PMID: 30281893 Clinical Trial.
https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fpubmed.ncbi.nlm.nih.gov%2f30281893%2f&c=E,1,4gBnj_ScTnVhwBTw8ZTLp7S7mC68k2Ma4z6o9uVSt3oJ29TSjrsvvscJ806oNWYD5Q-x6LPig5RzvNMUeugWqcO0WgmmGaUleVGPL3P5mF2xSG9luodBIjf3aL0,&typo=1
Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.
Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat AM, Konety B, Malmström PU, McKiernan J, O'Donnell M, Patel S, Pohar K, Resnick M, Sankin A, Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.
Nat Rev Urol. 2019 Jun;16(6):377-386. doi: 10.1038/s41585-019-0184-4.
PMID: 31019310 Free PMC article. Review.
https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fpubmed.ncbi.nlm.nih.gov%2f31019310%2f&c=E,1,SiwfCe--twcu5pXZsctjLaMPG8nQqX82kEUrYOOUE1auaoEsBeKFWYz6eGREJCQrwprmuu7WsGOqtGDo5dsiXre3VU6hpa3iX551d5Ia2GM,&typo=1
Blue Light Cystoscopy: Indications and Outcomes.
Pohar KS.
Curr Urol Rep. 2020 Apr 4;21(5):19. doi: 10.1007/s11934-020-0966-5.
PMID: 32248340 Review.
https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fpubmed.ncbi.nlm.nih.gov%2f32248340%2f&c=E,1,ajK_ub6b759V3FWcq_DlZ0ZIofblOPldOaIwG1sz9awMphcRjdmSv_YwcmzyxYubp9J4Hy14OBpJrN3Gv2hKK-ehP7Nd9Xit7RpuW7syBt3qVB9flt0,&typo=1
The use of blue light flexible cystoscopy with hexaminolevulinate & the diagnosis of bladder cancer.
Clinton TN, Lotan Y.
Future Oncol. 2018 Nov;14(27):2805-2810. doi: 10.2217/fon-2018-0328. Epub 2018 Jun 21.
PMID: 29925279 Review.
https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fpubmed.ncbi.nlm.nih.gov%2f29925279%2f&c=E,1,whPk_v4XrIxILe80ufZnSni-pAKcei3RQJoFdTGjQgFsNsLZFQraNjCLoGd3p7-TTII0CbCh8BGxUyYsyKttofqyjGCc9Ve2ewBxd_DuOmQ_gshzKmE66G2M&typo=1
The Impact of Blue Light Cystoscopy on the Diagnosis and Treatment of Bladder Cancer.
Pietzak EJ.
Curr Urol Rep. 2017 May;18(5):39. doi: 10.1007/s11934-017-0685-8.
PMID: 28324275 Review.
https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fpubmed.ncbi.nlm.nih.gov%2f28324275%2f&c=E,1,W0c5Fn4GCN2H3rtQplYWLCbVTk_uFTkkU7e4rNbAfBumNzFWNXJ0DnWgNNx0cOuSrLmYDH0LzmRDP2Bce4DNriM4NCAGjKxSO3vKvL2m&typo=1
Blue Light Cystoscopy in Patients with Suspected Non-Muscle Invasive Bladder Carcinoma: A Review of Clinical Utility [Internet].
Tran K, Severn M.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Feb 15.
PMID: 28825777 Free Books & Documents. Review.
https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fpubmed.ncbi.nlm.nih.gov%2f28825777%2f&c=E,1,OxXvuw2LyEwXw6BW3Hqpd6VZSWJHa4exUeq4sZEc0w9UEOnvq6DsUacIPSua_2p73L30sdhxjeaYbDSCe497JrY0-UDEsI4fSYsQIZ6iw3HKMcyiAroLUmHHrl4,&typo=1
Role of blue-light cystoscopy in the management of non-muscle invasive bladder cancer.
Pignot G.
Prog Urol. 2015 Sep;25(10):607-15. doi: 10.1016/j.purol.2015.05.003. Epub 2015 Jun 15.
PMID: 26088583 Review. French.
https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fpubmed.ncbi.nlm.nih.gov%2f26088583%2f&c=E,1,hcCQCQVcIwDqAGboIt6-th7Gx8jq0hMt5rzvj45dI6FsgyTOmsTjYFmnMVz0kGN5jZYb4k8_-XCW5yB_IQ1KwEmag3Rd-NumaK1PemoUOcm1hg,,&typo=1
